TACSTD2 and prostate carcinoma: In prostate cancer, GSE1 is frequently upregulated, whereas TACSTD2 exhibits downregulation; this inverse correlation promotes metastatic dissemination, castration resistance, and disease progression, while also modulating clinical and immune parameters in patients (64).